INT28951

Context Info Confidence 0.59 First Reported 1989 Last Reported 2011 Negated 2 Speculated 6 Reported most in Body Documents 133 Total Number 141 Disease Relevance 75.77 Pain Relevance 18.90

signal transduction (IGF1) extracellular space (IGF1) extracellular region (IGF1)

Anatomy Link Frequency blood 6 plasma 5 liver 4 fat 2 Thyroid 2 IGF1 (Homo sapiens)

Pain Link Frequency Relevance Heat Pain 155 100.00 Enkephalin 2 100.00 rheumatoid arthritis 685 99.98 Bioavailability 16 99.92 Inflammation 445 99.84 anesthesia 421 99.84 headache 44 99.84 COX2 3 99.76 Paracetamol 27 99.64 Fibrositis 132 99.60

Disease Link Frequency Relevance Heat Body Weight 39 100.00 Chronic Fatigue Syndrome 16 100.00 Glioma 7 100.00 Rheumatoid Arthritis 686 99.98 Laron Syndrome 93 99.92 Obesity 387 99.88 INFLAMMATION 492 99.84 Nicotine Addiction 358 99.84 Headache 39 99.84 Polio 2 99.84

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Treatment of severe primary IGF-1 deficiency

Negative_regulation (deficiency) of IGF-1

1) Confidence 0.59 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2724186 Disease Relevance 0.16 Pain Relevance 0

This problem is more apparent for the elderly where these events are superimposed on an age-related loss in IGF-1 activity.

Negative_regulation (loss) of IGF-1

2) Confidence 0.58 Published 2006 Journal BMC Complement Altern Med Section Body Doc Link PMC1456997 Disease Relevance 0.56 Pain Relevance 0.27

Supplemental IGF-1 restored linear growth in these models, linking the suppression of IGF-1 to compromised anabolic activity [43].

Negative_regulation (suppression) of IGF-1

3) Confidence 0.58 Published 2006 Journal BMC Complement Altern Med Section Body Doc Link PMC1456997 Disease Relevance 0.54 Pain Relevance 0.23

A reduction of IGF-I levels even in the final stage metastasized prostate cancer may play a major role.

Negative_regulation (reduction) of IGF-I associated with reprotox - general 1

4) Confidence 0.57 Published 2008 Journal J. Neurosurg. Section Abstract Doc Link 18826367 Disease Relevance 1.17 Pain Relevance 0.47

In these critically-ill patients, the fall in maximal diaphragmatic force over several days parallels the reduction in muscular mass as a result of oxidative myofibrillar injuries, increased protease activity and downregulation of the insulin-like growth factor-I.

Negative_regulation (downregulation) of insulin-like growth factor-I associated with injury

5) Confidence 0.57 Published 2007 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2699974 Disease Relevance 0.94 Pain Relevance 0.18

Despite reductions in IGF-1 levels to as low as 239 ng/ml after seven months, the lanreotide dose was increased initially to 90 mg every four weeks, and then to 120 mg every four weeks one month later.

Negative_regulation (reductions) of IGF-1

6) Confidence 0.57 Published 2010 Journal J Med Case Reports Section Body Doc Link PMC2845144 Disease Relevance 0.40 Pain Relevance 0.15

Although she had no overt symptoms of acromegaly, her cardiac function was improved when her GH and IGF-1 levels were reduced as she had less dyspnoea.

Negative_regulation (reduced) of IGF-1 associated with acromegaly and dyspnea

7) Confidence 0.57 Published 2010 Journal J Med Case Reports Section Body Doc Link PMC2845144 Disease Relevance 0.80 Pain Relevance 0.06

The reasons for this are unclear as the subjects were otherwise in good health and while rheumatic heart disease is associated with reduced serum IGF-1, rheumatoid arthritis is not [61].

Negative_regulation (reduced) of IGF-1 in heart associated with rheumatic heart disease and rheumatoid arthritis

8) Confidence 0.53 Published 2007 Journal BMC Complement Altern Med Section Body Doc Link PMC2131759 Disease Relevance 0.27 Pain Relevance 0.12

Thyroid function was suppressed to reduce IGF-1 levels in glioma patients and high-dose tamoxifen administered.

Negative_regulation (reduce) of IGF-1 in Thyroid associated with glioma

9) Confidence 0.52 Published 2003 Journal Anticancer Res. Section Abstract Doc Link 12680157 Disease Relevance 0.34 Pain Relevance 0.14

The present study shows that it actually also is possible to influence the postoperative decrease in IGF-1 with a balanced amino acid mixture supply.

Spec (possible) Negative_regulation (decrease) of IGF-1

10) Confidence 0.49 Published 2007 Journal Nutr Metab (Lond) Section Body Doc Link PMC1779788 Disease Relevance 0.64 Pain Relevance 0

During the study period Group B, the Ringer-group, exhibited a decrease in IGF-1 (from 139 to 91 ?

Negative_regulation (decrease) of IGF-1

11) Confidence 0.49 Published 2007 Journal Nutr Metab (Lond) Section Body Doc Link PMC1779788 Disease Relevance 0 Pain Relevance 0.07

However, Skjaerbaek et al. found unchanged levels of free IGF-1 despite a significant decrease of total IGF-1 after surgery[45].

Negative_regulation (decrease) of IGF-1

12) Confidence 0.49 Published 2007 Journal Nutr Metab (Lond) Section Body Doc Link PMC1779788 Disease Relevance 0.51 Pain Relevance 0

IGF-1, however, decreased in both group B (139 to101 ?

Negative_regulation (decreased) of IGF-1

13) Confidence 0.49 Published 2007 Journal Nutr Metab (Lond) Section Body Doc Link PMC1779788 Disease Relevance 0 Pain Relevance 0.06

After 12 weeks of treatment, mean (+/- SEM) GH levels decreased from 24.8 +/- 12.5 to 6.9 +/- 3.3 ng/ml and mean serum IGF-I levels decreased from 689 +/- 282 to 430 +/- 216 ng/ml.

Negative_regulation (decreased) of serum IGF-I

14) Confidence 0.48 Published 1999 Journal Endocr. J. Section Abstract Doc Link 10426587 Disease Relevance 0.38 Pain Relevance 0.16

Furthermore, insulin-like growth factor (IGF)-1 levels are frequently reduced in patients with FM.

Negative_regulation (reduced) of insulin-like growth factor associated with fibrositis

15) Confidence 0.47 Published 1999 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 10487713 Disease Relevance 1.09 Pain Relevance 0.49

Indications for treatment of severe IGF-1 deficiency

Negative_regulation (deficiency) of IGF-1

16) Confidence 0.43 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2724186 Disease Relevance 0.32 Pain Relevance 0

Clinical characteristics of primary IGF-1 deficiency

Negative_regulation (deficiency) of IGF-1

17) Confidence 0.43 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2724186 Disease Relevance 0.70 Pain Relevance 0

Etiology of primary IGF-1 deficiency

Negative_regulation (deficiency) of IGF-1

18) Confidence 0.43 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2724186 Disease Relevance 0.57 Pain Relevance 0

Primary IGF-1 deficiency is a rare disease, mainly resulting in very short stature; (2) Mecasermin is a recombinant IGF-1 marketed for this indication as a twice daily subcutaneous injection; (3) Clinical evaluation is mainly based on a non-comparative follow-up study of 76 children with an average age of 7 years, some of whom were treated for 8 years.

Negative_regulation (deficiency) of IGF-1 associated with rare diseases and growth problems

19) Confidence 0.43 Published 2009 Journal Prescrire Int Section Abstract Doc Link 19637420 Disease Relevance 0.35 Pain Relevance 0.08

While there are a number of factors including cytokines and poor nutrition, that are thought to contribute to a disruption in IGF-1 functionality [58], the present observations are the first to report that autocrine activation of IGF-1 gene expression in target tissues is a possible solution to these problems.

Negative_regulation (disruption) of IGF-1 associated with cytokine

20) Confidence 0.43 Published 2006 Journal BMC Complement Altern Med Section Body Doc Link PMC1456997 Disease Relevance 0.24 Pain Relevance 0.13

General Comments

This test has worked.